View More Recent Stories

Feb 25, 2025 01:07PM AxoGen, Inc. (AXGN) PT Raised to $25 at Leerink Partners
Feb 25, 2025 10:41AM AxoGen, Inc. (AXGN) PT Raised to $24 at Cantor Fitzgerald
Feb 25, 2025 07:16AM AxoGen (AXGN) Tops Q4 EPS by 4c
Feb 3, 2025 08:08AM AxoGen (AXGN) Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Feb 3, 2025 06:32AM AxoGen, Inc. (AXGN) PT Raised to $22 at Canaccord Genuity
Jan 10, 2025 08:02AM AxoGen (AXGN) Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024
Nov 7, 2024 08:29AM AxoGen (AXGN) Tops Q3 EPS by 6c
Sep 6, 2024 07:00AM AxoGen (AXGN) Completes Submission of BLA to U.S. Food and Drug Administration for Avance Nerve Graft®
Aug 8, 2024 07:19AM AxoGen (AXGN) Tops Q2 EPS by 11c, provides guidance
Aug 8, 2024 07:05AM AxoGen (AXGN) Appoints Michael Dale as CEO
View More Recent Stories